ESTRO 2024 - Abstract Book

S1524

Clinical - Lower GI

ESTRO 2024

(61.9% vs. 37.9% in concomitant boost and conventional arms, respectively (Odd Ratio= 1.63, 95%CI: 0.92-2.89; p=0.08). There was no grade 3 and 4 toxicity.

Conclusion

Based on our study there was a non-significant improvement in complete response and down-staging in intensified CRT in comparison to conventional CRT. The final results may show stronger relationships between dose intensification and oncological outcomes.

Conventional arm

Concomitant boost arm

Total

No of Patient

37

33

70

Male

30(81.1%)

20(60.6%)

50(71.4%)

Gender

Female

7(18.9%)

13(39.4%)

20(28.6%)

stage II

7(18.9%)

5(15.2%)

12(17.1%)

stage III

30(81.1%)

28(84.8%)

58(82.8%)

T3

28(75.7%)

28(84.8%)

56(80%)

T4

9(24.3%)

5(15.2%)

14(20%)

NÅ

30(81.1%)

28(84.8%)

58(82.8%)

CRMÅ

7(33.3%)

4(19%)

11(26.2%)

Classic adenocarcinoma

32(86.5%)

31(93.9%)

63(90%)

Histology

Mucinous

2(5.4%)

2(6.1%)

4(5.7%)

Conclusion:

Based on our study there was a non-significant improvement in complete response and down-staging in intensified CRT in comparison to conventional CRT. The final results may show stronger relationships between dose intensification and oncological outcomes.

Keywords: Rectal cancer; Chemoradiotherapy

1822

Digital Poster

Impact of DPD deficiency on outcomes for rectal cancer patients receiving concurrent chemo-radiation

Louise M Reeves 1 , Lucy Buckley 1 , Nooreen Alam 1 , Claire Arthur 1 , Imogen Hemy 1 , Victoria Lavin 1 , Peter Mbanu 1 , Mark Saunders 1 , Pete Bridge 2 1 The Christie NHS Foundation Trust, Radiotherapy, Manchester, United Kingdom. 2 The University of Liverpool, School of Health Sciences, Liverpool, United Kingdom